US 11,806,393 B2
Flavivirus peptide sequences, epitopes, and methods and uses thereof
Sujan Shresta, La Jolla, CA (US)
Assigned to La Jolla Institute for Allergy and Immunology, La Jolla, CA (US)
Filed by La Jolla Institute for Allergy and Immunology, La Jolla, CA (US)
Filed on Aug. 9, 2019, as Appl. No. 16/537,447.
Application 16/537,447 is a continuation in part of application No. PCT/US2018/017554, filed on Feb. 9, 2018.
Claims priority of provisional application 62/845,414, filed on May 9, 2019.
Claims priority of provisional application 62/457,753, filed on Feb. 10, 2017.
Prior Publication US 2020/0237892 A1, Jul. 30, 2020
Int. Cl. A61K 39/12 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); C07K 7/06 (2006.01)
CPC A61K 39/12 (2013.01) [C07K 7/06 (2013.01); G01N 33/505 (2013.01); G01N 33/6893 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A method of inducing, enhancing, or sustaining an immune response against Zika virus in a subject, the method comprising contacting T cells of the subject with an effective amount of a composition comprising an acceptable carrier or diluent, and one or more peptides selected from the group of a peptide consisting of an amino acid sequence set forth in any one of SEQ ID NO: 125 to SEQ ID NO: 129.